The Cancer Letter

Inside information on cancer research and drug development

Beckerle reinstated as director of Huntsman Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Nearly 100 cancer patients and others gather for a march to University of Utah President David Pershing’s office on April 24, calling for the reinstatement of Mary Beckerle as director and CEO of the Huntsman Cancer Institute.Cover Photo by Scott G Winterton, Deseret NewsA week after her abrupt firing, Mary Beckerle is back in her job as director and CEO of the Huntsman Cancer Institute.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Matthew Bin Han Ong
Senior Editor
Table of Contents

YOU MAY BE INTERESTED IN

Capitol Hill

House GOP leaders propose “streamlining” NIH into 15 institutes and centers
Plan calls for slashing ARPA-H, adding oversight to infectious disease research

Two Republican leaders in the House of Representatives have published a “framework” for reforming NIH—consolidating the agency’s 27 institutes and centers into 15—arguing that a fundamental rethinking of NIH’s structure would fix what they describe as a “system rife with stagnant leadership, as well as research duplication, gaps, and misconduct.”
By Matthew Bin Han Ong
Guest Editorial

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi
In the Archives

Two years before the role of EGFR mutations was understood, ODAC recommended accelerated approval of Iressa for NSCLC

On Sept. 24, 2002, the Oncologic Drugs Advisory Committee recommended an accelerated approval for AstraZeneca’s Iressa (gefitinib). The recommendation concluded a meeting where ODAC weighed whether the drug, an EGFR tyrosine kinase inhibitor, could benefit patients with resistant or refractory non-small cell lung cancer as a third-line therapy.
Byline
Matthew Bin Han Ong
Senior Editor
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account